We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · September 08, 2020

Luminal B, Premenopause

Roberto Coello

 

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Levon Badalyan

    I also would consider PARP inhibitors if BRCA germline testing positive, and review of HER2 status.


  • Keith Brunckhorst

    I would prefer single agent sequential chemotherapy, doctor's choice of drug and follow closely.


  • Raul Gerardo Ramirez Medina

    Re biopsy, and Now if is possible , perform biomarkers as PI3k mut, BRCA to bring Target therapy If possible .


  • Sep 19, 2020

    Pending Moderator approval.
    Delete

Further Reading